, Volume 72, Issue 18, pp 2365–2373 | Cite as

Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients

A Meta-Analysis
  • Folgerdiena M. de Vries
  • Petra Denig
  • Koen B. Pouwels
  • Maarten J. Postma
  • Eelko Hak
Systematic Review



Patients with diabetes mellitus are at increased risk of developing cardiovascular disease. Controlling lipid levels has a preventive effect on the occurrence of major cardiovascular and cerebrovascular events. Individual trials have shown varying data on the efficacy of treatment with lipid-lowering statin therapy in the primary prevention of such events in diabetes.


The objective of this study was to assess the efficacy of statins in the primary prevention of the first-time occurrence of a major cardiovascular or cerebrovascular event in diabetic patients. Secondary endpoints were fatal/non-fatal stroke, fatal/non-fatal myocardial infarction and all-cause mortality.


A systematic search for trial reports was conducted in PubMed, EMBASE, The Cochrane library and clinicaltrials.gov for the years 1966–2011. Reference lists of reviews and meta-analyses of related subjects were searched. High-quality, randomized, double-blinded clinical trials comparing a statin with placebo for the primary prevention of major cardiovascular and cerebrovascular events in diabetic patients were selected. Only large studies with a minimum of 500 diabetic participants followed-up for at least 2 years were included. Endpoints were major cardiovascular and cerebrovascular events.

Trial and patient characteristics were extracted by three researchers. The quality of the included studies was tested with the Jadad score. The combined effect on primary as well as secondary endpoints was measured with a fixed-effect model. Publication bias was examined with a funnel plot.


Four trials were included, for a total of 10 187 participants. Treatment with statins in the primary prevention of major cardiovascular and cerebrovascular events in diabetic patients resulted in a significant relative risk (RR) reduction in the first-time occurrence of major cardiovascular or cerebrovascular events (RR 0.75, 95% CI 0.67–0.85), fatal/non-fatal stroke (RR 0.69, 95% CI 0.51–0.92) and fatal/non-fatal myocardial infarction (RR 0.70, 95% CI 0.54–0.90) and a non-significant RR reduction in all-cause mortality (RR 0.84, 95% CI 0.65–1.09). Among the studies there was non-significant heterogeneity in the individual effect estimates and no publication bias.


Exclusion criteria and endpoints varied slightly between studies. The type and dosing of statin therapy differed between studies. Non-compliance in the statin treatment group and the use of statin treatment in the placebo group could have led to lower risk reductions.


Treatment with statins in primary prevention among diabetic patients has a significant beneficial effect on event rates of the first-time occurrence of a major cardiovascular or cerebrovascular event, fatal/non-fatal stroke and fatal/non-fatal myocardial infarction. There was a non-significant RR reduction in all-cause mortality.


Diabetic Patient Statin Simvastatin Atorvastatin Primary Prevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organisation. Global health observatory: causes of death in 2008 [online]. Available from URL: http://www.who.int/gho/mortality_burden_disease/causes_death_2008/en/index.html [Accessed 2012 Jan 18]
  2. 2.
    American Heart Association. Cardiovascular disease and diabetes: statistics update 2010 [online]. Available from URL: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp [Accessed 2012 Jan 18]
  3. 3.
    Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 1998 Jan; 21(1): 69–75PubMedCrossRefGoogle Scholar
  4. 4.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct; 366(9493): 1267–78PubMedCrossRefGoogle Scholar
  5. 5.
    Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and out-come with patients in randomised trials. BMJ 2005 Apr 9; 330(7495): 821PubMedCrossRefGoogle Scholar
  6. 6.
    Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011 Jan 19; (1): CD004816Google Scholar
  7. 7.
    Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan 12; 371: 117–25PubMedCrossRefGoogle Scholar
  8. 8.
    Knopp RH, D’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006 Jul; 29(7): 1478–85PubMedCrossRefGoogle Scholar
  9. 9.
    Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009 Jun 30; 338: b2376PubMedCrossRefGoogle Scholar
  10. 10.
    Chen YH, Feng B, Chen ZW. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp Clin Endocrinol Diabetes 2012 Feb; 120(2): 116–20PubMedCrossRefGoogle Scholar
  11. 11.
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360(9346): 1623–30PubMedCrossRefGoogle Scholar
  12. 12.
    Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001 Jun 7; 323(7303): 42–6PubMedCrossRefGoogle Scholar
  13. 13.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 Feb; 17(1): 1–12PubMedCrossRefGoogle Scholar
  14. 14.
    Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes. Diabetes Care 2005 May; 28: 1151–7PubMedCrossRefGoogle Scholar
  15. 15.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21–27; 364: 685–96PubMedCrossRefGoogle Scholar
  16. 16.
    Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 Jun 14; 361(9374): 2005–16PubMedCrossRefGoogle Scholar
  17. 17.
    Cook RJ, Sackett D. The number needed to treat: a clinically useful measure of treatment. BMJ 1995 Feb 18; 310(6977): 452–4PubMedCrossRefGoogle Scholar
  18. 18.
    Scholten RJ, Kostense PJ, Assendelften WJ, et al. The practice of systematic reviews: IV. Pooling results from separate studies [in Dutch]. Ned Tijdschr Geneeskd 1999; 143: 786–91PubMedGoogle Scholar
  19. 19.
    Review manager (RevMan) [computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011Google Scholar
  20. 20.
    Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. Part 3 fixed-effect versus random effects models. Chichester: John Wiley & Sons, Ltd, 2009: 59–86Google Scholar
  21. 21.
    Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008 Nov 27; 8: 79PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6; 327(7414): 557–60PubMedCrossRefGoogle Scholar
  23. 23.
    The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002 Dec 18; 288(23): 2998–3007CrossRefGoogle Scholar
  24. 24.
    Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006 Sep 30; 368(9542): 1155–63PubMedCrossRefGoogle Scholar
  25. 25.
    Wanner C, Krane V, Marz W, et al., German Diabetes and Dialysis Study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 2005; 353: 238–48CrossRefGoogle Scholar
  26. 26.
    Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998 Mar 1; 81(5): 582–7PubMedCrossRefGoogle Scholar
  27. 27.
    Grundy S, Cleeman JI, Merz NB, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials of the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 Jul 13; 100(2): 227–39CrossRefGoogle Scholar
  28. 28.
    Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul; 32(14): 1769–818PubMedCrossRefGoogle Scholar
  29. 29.
    Rutten GEHM, De Grauw WJC, Nijpels G. NHG-Standaard diabetes mellitus type 2. Huisarts Wet 2006; 49(3): 137–52Google Scholar
  30. 30.
    Wiersma TJ, Goudswaard AN. NHG-standard cardiovascular risk management [in Dutch]. Houten: Bohn Stafleu van Loghum, 2006Google Scholar
  31. 31.
    Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009 Dec; 10(18): 2973–85PubMedCrossRefGoogle Scholar
  32. 32.
    Donnelly LA, Doney ASF, Morris AD. Long-term adherence to statin treatment in diabetes. Diabetic Med 2008; 25(7): 850–5PubMedCrossRefGoogle Scholar
  33. 33.
    Olafsdottir E, Aspelund T, Sigurdsson G, et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older patients: the population-based AGES-Reykjavik Study. BMJ Open 2011 Jan 1; 1(1): e000132PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Folgerdiena M. de Vries
    • 1
  • Petra Denig
    • 2
  • Koen B. Pouwels
    • 1
  • Maarten J. Postma
    • 1
  • Eelko Hak
    • 1
  1. 1.Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomicsUniversity of GroningenGroningenthe Netherlands
  2. 2.Department of Clinical PharmacologyUniversity of Groningen, University Medical CenterGroningenthe Netherlands

Personalised recommendations